| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Baochen Zhu, Yang Xiao, Ruiheng Liao, Hanxing Zhao, Xuewen Xu, Yan'ge Zhan. [Emergency management and perioperative strategies for intra-tumoral hemorrhage in neurofibromatosis type 1-related giant plexiform neurofibroma]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. vol 38. issue 10. 2024-10-21. PMID:39433490. |
to review the emergency management and perioperative strategies for ruptured neurofibromatosis type 1 (nf1)-related giant plexiform neurofibroma (pnf), providing a systematic treatment protocol to improve the therapeutic outcomes and quality of life for patients with giant pnf. |
2024-10-21 |
2024-10-24 |
Not clear |
| Nour Al Ghriwati, Paige Little, Staci Martin, Mary Anne Tamula, Brigitte C Widemann, Pamela L Wolter. Parent-child discrepancies in reports of child psychosocial functioning in neurofibromatosis type 1. Journal of family psychology : JFP : journal of the Division of Family Psychology of the American Psychological Association (Division 43). 2024-10-17. PMID:39418437. |
this study examined the concordance of parent proxy- and child self-report of child behavioral and social-emotional functioning on selected behavior assessment system for children-second edition subscales in families of children with nf1 and plexiform neurofibroma tumors (pnfs). |
2024-10-17 |
2024-10-20 |
Not clear |
| Andi Ahmad Thoriq Pratama, M Hidayat Surya Atmaj. The role of multimodality imaging in diffuse pelvicoabdominal plexiform neurofibroma: A rare case report. Radiology case reports. vol 19. issue 12. 2024-09-19. PMID:39296740. |
pelvicoabdominal plexiform neurofibroma is a rare and complicated form of type 1 neurofibromatosis (nf1), distinguished by developing benign nerve sheath tumors in the pelvis and abdomen. |
2024-09-19 |
2024-09-21 |
Not clear |
| Amedeo A Azizi, Darren Hargrave, João Passos, Pierre Wolkenstein, Thorsten Rosenbaum, Claudia Santoro, Verena Rosenmayr, Thomas Pletschko, Paolo A Ascierto, Héctor Salvador Hernánde. Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-oncology practice. vol 11. issue 5. 2024-09-16. PMID:39279781. |
selumetinib is the first approved treatment for pediatric patients with neurofibromatosis type 1 (nf1) and symptomatic, inoperable plexiform neurofibromas (pn) in the eu and us, as well as in multiple other countries. |
2024-09-16 |
2024-09-18 |
Not clear |
| Fahad A Bashiri, Khaled Hundallah, Musaad Abukhaled, Mossaed Mohammed Alyahya, Amna Al Futaisi, Daniah Alshowaeir, Asmaa Al Tawari, Shaker Abdullah, Ata Ur Rehman Maaz, Eman Taryam AlShamsi, Walaa Alshuaibi, Faisal Alotaibi, Hesham Aldhalaa. Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations. Frontiers in oncology. vol 14. 2024-09-11. PMID:39257551. |
the approval and widespread availability of mitogen-activated protein kinase (mek) inhibitors such as selumetinib for nf1-related plexiform neurofibromas have revolutionized the standard of care for patients with nf1, however their effective utilization hinges on early recognition of nf1. |
2024-09-11 |
2024-09-13 |
Not clear |
| Kathryn M Lemberg, Andrea M Gross, Lauren M Sproule, David J Liewehr, Eva Dombi, Andrea Baldwin, Seth M Steinberg, Miriam Bornhorst, Maya Lodish, Jaishri O Blakeley, Brigitte C Wideman. Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment. Pediatric research. 2024-08-29. PMID:39198589. |
in children and adolescents/young adults (caya) with neurofibromatosis type i (nf1), associations between anthropometric measurements, plexiform neurofibroma (pnf) tumor volume (tv), and treatment history are unknown. |
2024-08-29 |
2024-09-01 |
Not clear |
| Chan Wu, Mohammed Salman Shazeeb, Kotchaphorn Mangkalaphiban, George Han, Ahmet Peker, Zubir S Rentiya, Matthew J Gounis, Allan Jacobso. Investigating therapeutic nonsense suppression in a neurofibromatosis mouse model. Experimental neurology. 2024-08-06. PMID:39106942. |
plexiform neurofibromas, one of many nf1 manifestations, are benign peripheral nerve sheath tumors occurring in up to 50% of nf1 patients. |
2024-08-06 |
2024-08-09 |
mouse |
| Yuehua Li, Jun Liu, Jingxuan Huang, Chengjiang Wei, Lingling Ge, Manhon Chung, Beiyao Zhu, Zizhen Guo, Tingting Zheng, Haibo Li, Yihui Gu, Wei Wang, Qingfeng Li, Zhichao Wan. Reduced PTPRS expression promotes epithelial-mesenchymal transition of Schwann cells in NF1-related plexiform neurofibromas. Cancer letters. 2024-08-02. PMID:39094827. |
plexiform neurofibromas (pnfs) are a prevalent and severe phenotype associated with nf1, characterized by a high teratogenic rate and potential for malignant transformation. |
2024-08-02 |
2024-08-06 |
Not clear |
| Kyungmin Ji, George J Schwenkel, Raymond R Mattingly, Harini G Sundararaghavan, Zheng Gang Zhang, Michael Chop. A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. Cancers. vol 16. issue 14. 2024-07-27. PMID:39061138. |
plexiform neurofibromas (pns) occur in about a half of neurofibromatosis type 1 (nf1) patients and have garnered significant research attention due to their capacity for growth and potential for malignant transformation. |
2024-07-27 |
2024-07-29 |
Not clear |
| Kyungmin Ji, George J Schwenkel, Raymond R Mattingly, Harini G Sundararaghavan, Zheng Gang Zhang, Michael Chop. A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. Cancers. vol 16. issue 14. 2024-07-27. PMID:39061138. |
nf1 plexiform neurofibroma (pnf1) is a complex tumor composed of schwann cell-derived tumor cells ( |
2024-07-27 |
2024-07-29 |
Not clear |
| Stephanie J Bouley, Andrew V Grassetti, Robert J Allaway, Matthew D Wood, Helen W Hou, India R Burdon Dasbach, William Seibel, Jimmy Wu, Scott A Gerber, Konstantin H Dragnev, James A Walker, Yolanda Sanche. Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss. Journal of cell science. 2024-07-17. PMID:39016685. |
neurofibromatosis type 1, a genetic disorder caused by germline mutations in nf1, predisposes patients to the development of tumors, including cutaneous and plexiform neurofibromas (cns and pns), optic gliomas, astrocytomas, juvenile myelomonocytic leukemia, high-grade gliomas, and malignant peripheral nerve sheath tumors (mpnsts), which are chemotherapy- and radiation-resistant sarcomas with poor survival. |
2024-07-17 |
2024-07-19 |
Not clear |
| Hyery Kim, Hee Mang Yoon, Eun Key Kim, Young Shin Ra, Hyo-Won Kim, Mi-Sun Yum, Min-Jee Kim, Jae Suk Baek, Yu Sub Sung, Sang Min Lee, Hyeong-Seok Lim, Byung Joo Lee, Hyun Taek Lim, Dohyung Kim, Jihee Yoon, Hyunwoo Bae, Soojin Hwang, Yun-Ha Choi, Kyung Ah Kim, In Hee Choi, Seung Won Lee, Su-Jung Park, Beom Hee Le. Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro-oncology. 2024-07-08. PMID:38975694. |
the mek inhibitor, selumetinib, reduces plexiform neurofibroma (pn) in pediatric patients with neurofibromatosis type 1 (nf1). |
2024-07-08 |
2024-07-11 |
Not clear |
| Xuyi Yue, Erik Stauff, Shriya Boyapati, Sigrid A Langhans, Wenqi Xu, Sokratis Makrogiannis, Uchenna J Okorie, Azubuike M Okorie, Vinay V R Kandula, Heidi H Kecskemethy, Rahul M Nikam, Lauren W Averill, Thomas H Shaffe. PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer. Pharmaceuticals (Basel, Switzerland). vol 17. issue 6. 2024-06-27. PMID:38931352. |
plexiform neurofibromas (pnfs) are benign tumors commonly formed in patients with nf1. |
2024-06-27 |
2024-06-29 |
Not clear |
| Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, Jean-Philippe Brossea. Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma. PloS one. vol 19. issue 6. 2024-06-20. PMID:38900740. |
nf1 patients frequently develop a benign tumor in peripheral nerve plexuses called plexiform neurofibroma. |
2024-06-20 |
2024-06-23 |
mouse |
| Andrea M Gross, Colette Achée, Sarah E Hart, Lindsay Brewer, Andrea Baldwin, Pamela L Wolters, Brigitte C Wideman. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Future oncology (London, England). vol 20. issue 14. 2024-06-13. PMID:38869947. |
the sprint study included 50 children with neurofibromatosis type 1 (nf1) and plexiform neurofibroma (pn) that could not be removed with surgery. |
2024-06-13 |
2024-06-15 |
Not clear |
| Dorea P Jenkins, Brittany Turner-Ivey, Jody Fromm Longo, Steven L Carrol. Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models. Journal of visualized experiments : JoVE. issue 207. 2024-06-03. PMID:38829133. |
patients with the autosomal dominant tumor susceptibility syndrome neurofibromatosis type 1 (nf1) commonly develop plexiform neurofibromas (pns) that subsequently transform into highly aggressive malignant peripheral nerve sheath tumors (mpnsts). |
2024-06-03 |
2024-06-05 |
mouse |
| Archis R Bhandarkar, Shaan Bhandarkar, Dusica Babovic-Vuksanovic, Aditya Raghunathan, Jonathan Schwartz, Robert J Spinne. Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing. Journal of neuro-oncology. 2024-05-13. PMID:38739187. |
selumetinib is an fda-approved targeted therapy for plexiform neurofibromas in neurofibromatosis type 1(nf1) with durable response rates seen in most, but not all patients. |
2024-05-13 |
2024-05-27 |
Not clear |
| David Viskochil, Mariusz Wysocki, Maria Learoyd, Peng Sun, Karen So, Azura Evans, Francis Lai, Héctor Salvador Hernànde. Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas. Neuro-oncology advances. vol 6. issue 1. 2024-05-10. PMID:38721358. |
selumetinib is approved for the treatment of pediatric patients with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn) in multiple countries, including the usa (≥ 2 years). |
2024-05-10 |
2024-05-27 |
human |
| Maria Ioannou, Kriti Lalwani, Abiola A Ayanlaja, Viveka Chinnasamy, Christine A Pratilas, Karisa C Schrec. MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma. Molecular cancer therapeutics. 2024-05-07. PMID:38714355. |
loss of nf1 leads to hyperactive ras signaling, creating opportunity given the established efficacy of mek inhibitors (meki) in plexiform neurofibromas and some individuals with lgg. |
2024-05-07 |
2024-05-27 |
Not clear |
| Angela C Hirbe, Carina A Dehner, Eva Dombi, Vanessa Eulo, Andrea M Gross, Taylor Sundby, Alexander J Lazar, Brigitte C Wideman. Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. vol 44. issue 3. 2024-05-06. PMID:38710002. |
in the setting of nf1, mpnsts arise from malignant transformation of benign plexiform neurofibroma and borderline atypical neurofibromas. |
2024-05-06 |
2024-05-27 |
Not clear |